MariMed (MRMD) versus Its Rivals Financial Analysis

MariMed (OTC:MRMD) is one of 55 public companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its competitors? We will compare MariMed to similar businesses based on the strength of its earnings, risk, dividends, analyst recommendations, institutional ownership, profitability and valuation.

Earnings and Valuation

This table compares MariMed and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MariMed	$148.60 million	-$16.03 million	-2.53
MariMed Competitors	$310.32 million	-$49.81 million	-5.77

MariMed’s competitors have higher revenue, but lower earnings than MariMed. MariMed is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares MariMed and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MariMed	-8.95%	1.58%	0.53%
MariMed Competitors	-38.94%	-24.68%	-6.33%

Insider & Institutional Ownership

0.2% of MariMed shares are held by institutional investors. Comparatively, 15.8% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 19.0% of MariMed shares are held by insiders. Comparatively, 21.5% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for MariMed and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MariMed	0	0	0	1	4.00
MariMed Competitors	290	567	1085	86	2.48

As a group, “Medicinals & botanicals” companies have a potential upside of 78.89%. Given MariMed’s competitors higher possible upside, analysts plainly believe MariMed has less favorable growth aspects than its competitors.

Risk and Volatility

MariMed has a beta of 3.15, suggesting that its stock price is 215% more volatile than the S&P 500. Comparatively, MariMed’s competitors have a beta of 1.30, suggesting that their average stock price is 30% more volatile than the S&P 500.

Summary

MariMed beats its competitors on 8 of the 13 factors compared.

MariMed Company Profile

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.